美国消费者价格指数 (CPI) 数据 - 美国劳工部数据显示，3月份消费者价格指数 (CPI) 同比上涨3.3% [1] - 该涨幅远高于2月份2.4%的同比涨幅 [1]

Cotton price action is up 8 to 30 points so far on Thursday. Futures closed out the Thursday rally with contracts up 80 to 159 points across most contracts. The outside markets are generally supportive, with the US dollar index was $0.325 lower at $98.600. Crude oil was back up $4.06 on the day. The monthly update to the USDA balance sheet for cotton showed the US side unchanged at 4.4 million bales for carryout, as the cash average price was up a penny to 61 cents. The world balance sheet was up 0.65 mil ...

Wheat is starting off Friday with losses across the three markets. The wheat complex was weaker on Thursday, following an increased stocks number from USDA. Chicago SRW futures saw losses of 4 ¾ to 7 ¼ cents at the close. Open interest was down 15,543 contracts, as May dropped 21,480 contracts. KC HRW futures were down 4 ¾ to 8 ¼ cents on the session. OI was down 5,151 contracts on Thursday. MPLS spring wheat was down 4 ¾ to 5 ¾ cents in on the day. Crude oil was back up $4.06 on Thursday. Export Sales d ...

Corn prices are trading with 1 to 2 ½ cent losses on Friday morning as traders look to round out the week. Futures saw losses on Thursday, with contracts down 1 ½ to 3 ¼ cents.  Open interest was down 12,902 contracts on Thursday, mainly in the May, dropping 41,575 contracts. Some were rolling to July, up 28,073 contracts. The CmdtyView national average Cash Corn price was down 3 cents at $4.05 1/2. Export Sales data from Thursday morning showed 1.36 MMT in old crop corn sales for the week of April 2. Th ...

Soybeans are starting off Friday with 2 to 4 cent gains. Futures posted gains of ¼ to 4 cents on Thursday, led by the front months. Open interest suggested a rotation of ownership, up just 248 contracts. The cmdtyView national average Cash Bean price was up 3 3/4 cents at $10.97 1/2. Soymeal futures were up $1 to $3.50 on the day. Front month May is up $6.30 this morning. Soy Oil futures were up 28 to 39 points on Thursday. USDA released their monthly WASDE report Thursday morning showing a few changes i ...

公司估值与市场观点 - 通用汽车基于对2026财年调整后收益的6.5倍市盈率进行估值 [1] - 该估值水平仍使市场将其视为一家暴露于行业周期的传统汽车制造商 [1] 分析师投资方法论 - 投资策略结合长期信念持仓与战术性的行业轮动 [1] - 核心理念是投资的目的在于盈利而不仅仅是判断正确 [1] - 关注点在于未被充分覆盖的投资机会以及由动能驱动的行业板块 [1]

总体通胀情况 - 2026年3月消费者价格指数经季节调整后环比上涨0.9% 年通胀率因此达到3.3% [2] - 年通胀率3.3% 为2024年4月以来的最高水平 较2月的2.4%有所上升 [2] - 整体通胀数据与道琼斯共识预期一致 [2] 核心通胀情况 - 剔除食品和能源的核心价格涨幅较小 3月环比仅上涨0.2% 同比上涨2.6% [3] - 核心通胀两项数据均比预期低0.1个百分点 显示基础通胀更为受控 [3] - 医疗保健、个人护理以及二手车和卡车价格月度环比均出现下降 显示出一些通缩迹象 [3] 能源价格驱动因素 - 3月能源成本飙升10.9% 是推高整体通胀的主要动力 [2] - 汽油价格飙升21.2% 贡献了整体价格涨幅的近四分之三 [4] - 能源价格飙升主要归因于伊朗冲突的影响 [1][4] 近期发展与市场背景 - 自2月底开始的冲突后 美国与伊朗达成停火 4月能源价格已有所缓和 [4] - 美联储官员在3月会议上倾向于降息25个基点 但时机高度不确定 [5] - 市场此前已基本定价2026年剩余时间不会降息 [5] - 基础通胀路径已连续五年高于美联储目标 [4]

Gallagher Re, the reinsurance broking and advisory arm of Arthur J. Gallagher & Co., has announced the appointment of Miguel Araújo as the new leader of its Iberia business.Araújo brings a combination of technical expertise and commercial experience, supporting the development of solutions and the management of client relationships.Araújo will be responsible for overseeing operations and growth across the Iberian region.He is currently serving as Executive Director at Gallagher Re. Prior to this, he worked ...

投资组合策略 - 个人投资策略核心在于增长与股息收入相结合 旨在通过构建投资组合为轻松退休做准备 [1] - 投资组合构建侧重于股息收入的复利效应和资本增长 股息是策略的重要组成部分 [1] - 投资组合被设计为提供月度股息收入 并通过股息再投资和年度股息增长来实现收入增长 [1] 持仓披露 - 作者披露通过股票所有权、期权或其他衍生品方式 长期持有GPIQ、QYLD、JEPQ、QQQI、NVDA、AAPL的看多头寸 [1]

公司临床进展 - MetaVia宣布其用于治疗肥胖症的新型GLP-1/胰高血糖素双激动剂DA-1726的1期临床试验第3部分已对首位患者给药[1] - 第3部分试验包含两个为期16周的剂量递增队列，旨在评估一步和两步剂量递增策略，以安全达到更高目标剂量并进一步优化耐受性[1] - 该部分试验预计共招募40名肥胖但其他方面健康的成年受试者，分为两部分，每部分20人，按4:1随机分组（16人活性药物；4人安慰剂）[2] 试验设计与目标 - 第3A部分评估一步滴定方案：16 mg剂量持续4周，随后48 mg剂量持续12周[2] - 第3B部分评估两步滴定方案：16 mg剂量持续4周，32 mg剂量持续4周，随后64 mg剂量持续8周[2] - 研究将评估DA-1726的安全性、耐受性、药代动力学和药效学，主要终点包括不良事件、严重不良事件、治疗中出现的不良事件以及导致治疗中止的不良事件[2] - 次要和探索性终点包括药代动力学分析，以及对代谢、血糖、血脂、身体成分（包括体重、腰围、体重指数）和其他心脏代谢指标的评估[2] - 试验数据预计在2026年第四季度获得[2] 药物机制与前期数据 - DA-1726是一种新型胃泌酸调节素类似物，作为GLP1R/GCGR双激动剂，每周皮下注射一次，通过降低食欲和增加能量消耗来减轻体重[4] - 在临床前小鼠模型中，与领先的GLP-1受体激动剂司美格鲁肽相比，DA-1726实现了更好的减重效果[4] - 在临床前小鼠模型中，与替尔泊肽和survodutide相比，DA-1726在摄入更多食物的同时实现了相似的体重减轻，并且与survodutide相比，保留了瘦体重并显示出改善的降脂效果[4] - 在1期多剂量递增试验中，32 mg剂量的DA-1726在减重、血糖控制和腰围减少方面显示出同类最佳的潜力[4] - 在48 mg剂量下，已观察到约9%的体重减轻，同时腰围有意义的减少、血糖控制改善以及直接的肝脏获益早期信号，且耐受性良好[2] 公司战略与管线 - MetaVia是一家临床阶段生物技术公司，专注于变革心脏代谢疾病[5] - 公司目前正在开发用于治疗肥胖的DA-1726，以及用于治疗代谢功能障碍相关脂肪性肝炎的vanoglipel[5] - Vanoglipel是一种新型GPR119激动剂，可促进关键肠道肽GLP-1、GIP和PYY的释放，在临床前研究中显示出对肝脏炎症、脂质代谢、减重和葡萄糖代谢的积极影响[5][6] - 在2a期临床研究中，vanoglipel除了降糖作用外，还表现出直接的肝脏作用[6]